

Device (Vietnam) Company, Limited of Binh Duong Province, Vietnam; TCL Smart Screen Technology HK of New Territories, Hong Kong; TCL Moka International Ltd. of New Territories, Hong Kong; TTE Technology, Inc. of Irvine, California; Hisense Co., Ltd. of Shandong Province, China; Hisense USA Corporation of Suwanee, Georgia; and Hisense Electronics Manufacturing Company of America Corporation of Suwanee, Georgia (collectively, "Respondents"). The Office of Unfair Import Investigations is not participating in this investigation. *Id.* at 1674.

On July 10, 2026, non-party Dolby Laboratories, Inc. ("Dolby") filed a motion pursuant to Commission Rule 210.19, 19 CFR 210.19, to intervene as an intervenor with full participation rights as to the '168 and '751 patents. On July 22, 2026, Complainants filed an opposition to the motion. Dolby filed a reply in support of its motion on July 27, 2026. While no other responses were received, Dolby certifies that the Respondents do not oppose the motion.

On August 12, 2026, the ALJ issued the subject ID (Order No. 17) granting Dolby's motion. The ALJ has determined that Dolby should be granted intervenor status in this investigation, but not status as a respondent. The ID states that Dolby's participation in this investigation should begin with the issuance of the subject ID and that Dolby may participate as an intervenor, including with respect to all claims and defenses at issue in the investigation regarding the '168 and '751 patents. No petitions for review were filed.

The Commission has determined not to review the subject ID. The Commission vote for this determination took place on September 9, 2026.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.

Issued: September 9, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026-18715 Filed 9-11-26; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1763]

Importer of Controlled Substances Application: Irvine Labs, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Irvine Labs, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before October 14, 2026. Such persons may also file a written request for a hearing on the application on or before October 14, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on August 13, 2026, Irvine Labs, Inc., 7305 Murdy Circle, Huntington Beach, California 92647-3533, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Lysergic acid diethylamide.	7315	I
Marihuana Extract	7350	I
Marihuana	7360	I
Tetrahydrocannabinols	7370	I
Mescaline	7381	I
Peyote	7415	I
Diethyltryptamine	7434	I
Dimethyltryptamine	7435	I
Psilocybin	7437	I
Psilocyn	7438	I

The company plans to import bulk substances to support internal research, clinical trials, analytical purposes, and distribution to their customers. In reference to drug codes Marihuana Extract (7350), Marihuana (7360) and Tetrahydrocannabinols (7370), the company plans to import a raw plant material and extracts. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Justin Wood,

Deputy Assistant Administrator.

[FR Doc. 2026-18757 Filed 9-11-26; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1759]

Bulk Manufacturer of Controlled Substances Application: Cambrex High Point, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Cambrex High Point, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 13, 2026. Such persons may also file a written request for a hearing on the application on or before November 13, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on July 29, 2026, Cambrex High Point, Inc., 4180 Mendenhall Oaks Parkway, High Point, North Carolina 27265–8017, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug Code	Schedule
Oxymorphone	9652	II
Noroxymorphone	9668	II

The company plans to manufacture the above listed controlled substances in bulk for use as an internal intermediates and distribution to its customers. No other activities for these drug codes are authorized for this registration.

Justin Wood,
Deputy Assistant Administrator.

[FR Doc. 2026–18753 Filed 9–11–26; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Stipulation and Order of Settlement Under the Toxic Substances Control Act

On September 9, 2026, the Department of Justice lodged a proposed Stipulation and Order of Settlement with the United States District Court for the Southern District of New York in the lawsuit entitled *United States of America v. Estate of Harry D. Silverstein*, Civil Action No. 26 Civ. 7752.

The United States' complaint seeks injunctive relief pursuant to the Toxic Substances Control Act ("TSCA") and the Residential Lead-Based Paint Hazard Reduction Act of 1992 ("RLBPHRA"),

from the Estate of Harry D. Silverstein ("Silverstein"), relating to Silverstein's failure to make required disclosures to tenants in fourteen residential buildings entering into new and certain renewal leases about lead-based paint in their apartment as required by the Lead Disclosure Rule (24 CFR part 35, subpart A, and 40 CFR part 745, subpart F). After Silverstein passed away, his estate (the "Estate") continued to own and manage the residential buildings and again routinely violated lead paint safety regulations. Additionally, the United States seeks relief under TSCA for Silverstein's and the Estate's failures to comply with safe work practices and related requirements during renovations as required by the Renovation, Repair, and Painting Rule (40 CFR part 745, subpart E). The Stipulation and Order of Settlement requires the Estate to pay a \$4.0 million administrative penalty to the United States under TSCA and the RLBPHRA.

The publication of this notice opens a period for public comment on the Stipulation and Order of Settlement. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States of America v. Estate of Harry D. Silverstein*, D.J. Ref. No. 90–5–1–1–13168. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email	pubcomment-ees.enrd@usdoj.gov .
By mail	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, D.C. 20044–7611.

Any comments submitted in writing may be filed in whole or in part on the public court docket without notice to the commenter.

During the public comment period, the Stipulation and Order of Settlement may be examined and downloaded at this Justice Department website: <https://www.justice.gov/enrd/consent-decrees>. If you require assistance accessing the Stipulation and Order of Settlement, you may request assistance by email or

by mail to the addresses provided above for submitting comments.

Eric D. Albert,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2026–18628 Filed 9–11–26; 8:45 am]

BILLING CODE 4410–15–P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Final Supplemental Consent Decree Under the Clean Water Act

On September 9, 2026, the Department of Justice lodged a proposed final supplemental consent decree with the United States District Court for the District of North Dakota in the lawsuit entitled *United States of America and State of North Dakota v. Belle Fourche Pipeline Company*, Civil Action No. 1:22–00089–DLH–CRH.

The lawsuit seeks injunctive relief and civil penalties for violations of the Clean Water Act, the Pipeline Safety Laws, and North Dakota state law arising from the failure of Belle Fourche Pipeline Company's Bicentennial Pipeline approximately 17.4 pipeline miles west of the Skunk Hill station, in Billings County, North Dakota, on or about December 1, 2016, resulting in the discharge of oil into an unnamed tributary to Ash Coulee Creek (the "Ash Coulee spill"). Except for certain claims relating to remediation of the Ash Coulee spill site, referred to as the "Reserved Remediation Claims," the claims in the lawsuit were resolved by a Partial Consent Decree entered on October 2, 2023.

The proposed final supplemental consent decree would resolve the Reserved Remediation Claims and requires Belle Fourche Pipeline Company ("Defendant") to implement a Remediation Work Plan to address environmental impacts resulting from the Ash Coulee Spill. Subject to certain reservations, entering into and fully complying with the proposed final supplemental consent decree will also resolve Plaintiffs' claims, through the date of lodging, for any discharges or releases to surface water relating to the Ash Coulee Spill.

The publication of this notice opens a period for public comment on the final supplemental consent decree. Comments should be addressed to the Assistant Attorney General, Energy and Natural Resources Division, and should refer to *United States and State of North Dakota v. Belle Fourche Pipeline Company*, D.J. Ref. No. 90–5–1–1–11262/2. All comments must be